NDAORALTABLET
Approved
Jun 2025
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
3/8 — Basic
WIDAPLIK (telmisartan, amlodipine and indapamide) by R-Pharm US is angiotensin 2 receptor antagonists [moa]. First approved in 2025.
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
WIDAPLIK is a fixed-dose combination tablet containing telmisartan (angiotensin II receptor blocker), amlodipine (calcium channel blocker), and indapamide (thiazide diuretic) approved for oral treatment of hypertension. This triple-agent formulation works through complementary mechanisms: telmisartan blocks angiotensin II receptors, amlodipine dilates blood vessels, and indapamide reduces fluid volume. The combination targets patients requiring multi-drug antihypertensive therapy.
Growth11.5 years to LOE
Recently approved product in growth phase with zero competitive pressure, offering opportunity to establish market position on a newly launched asset.
Mechanism of Action
Angiotensin 2 Receptor Antagonists
Pharmacologic Class:
Angiotensin 2 Receptor Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
WIDAPLIK represents a launch-phase opportunity for professionals seeking to build a new brand from market entry with zero competitive interference. The 11.5-year patent protection and growth-stage lifecycle create stable, multi-year career progression potential in commercial and medical functions.
Brand ManagerField Sales Representative
Worked on WIDAPLIK at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.